NCT07070466View on ClinicalTrials.gov

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 12, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

September 1, 2028

Conditions
Stomach Cancer Stage IVEsophagus CancerStomach Cancer
Interventions
DRUG

Ivonescimab

Humanized immunoglobulin G1 monoclonal antibody

DRUG

5-Fluorouracil

Nucleoside metabolic inhibitor

DRUG

Oxaliplatin

Platinum-based drug and organoplatinum complex

DRUG

Leucovorin

5-formyl derivative of tetrahydrofolic acid

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Summit Therapeutics
All Listed Sponsors
collaborator

Summit Therapeutics

INDUSTRY

lead

Massachusetts General Hospital

OTHER